Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. METHODS: We performed a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Chunguo, Huang, Hui, Liu, Jia, Wang, Yanxun, Lu, Zhiwei, Xu, Zuojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467250/
https://www.ncbi.nlm.nih.gov/pubmed/23056564
http://dx.doi.org/10.1371/journal.pone.0047024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467250/
https://www.ncbi.nlm.nih.gov/pubmed/23056564
http://dx.doi.org/10.1371/journal.pone.0047024

Ejemplares similares